公开(公告)号：US20220089575A1

公开(公告)日：2022-03-24

申请号：US17538394

申请日：2021-11-30

Applicant: Metacrine, Inc.

Inventor： Nicholas D. SMITH ,  Steven P. GOVEK ,  Johnny Y. NAGASAWA ,  Karensa L. DOUGLAS ,  Andiliy G. LAI

IPC: C07D403/12 ,  C07D417/12 ,  C07D275/02 ,  C07D413/12 ,  C07D417/04 ,  C07D231/12 ,  C07D401/12 ,  C07D277/28 ,  A61P1/16 ,  C07D413/14 ,  C07D417/14 ,  C07D263/32 ,  C07D401/14

Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

公开(公告)号：US20230120914A1

公开(公告)日：2023-04-20

申请号：US17906585

申请日：2021-03-17

Applicant: Metacrine, Inc.

Inventor： Nicholas D. SMITH ,  Robert MANSFIELD

IPC: A61K9/16 ,  A61K31/4439 ,  A61K9/20

Abstract: Described herein are pharmaceutical formulations of a farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, and methods of using such pharmaceutical formulations in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

公开(公告)号：US20220002309A1

公开(公告)日：2022-01-06

申请号：US17287781

申请日：2019-10-23

Applicant: Metacrine, Inc.

Inventor： Nicholas D. SMITH ,  Andrew R. HUDSON ,  Mi CHEN ,  Johnny Y. NAGASAWA ,  Iriny BOTROUS

IPC: C07D491/107 ,  C07C237/24 ,  C07D309/14 ,  C07D295/185 ,  C07D257/04 ,  C07D241/18 ,  C07D273/01 ,  C07D498/08 ,  C07D307/22 ,  C07D307/93 ,  C07D233/60 ,  C07D205/04 ,  C07D231/12 ,  C07D241/04 ,  C07D239/42 ,  C07D239/34 ,  C07C311/14 ,  A61P1/16

Abstract: Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.

公开(公告)号：US20210347736A1

公开(公告)日：2021-11-11

申请号：US17276763

申请日：2019-09-17

Applicant: Metacrine, Inc.

Inventor： Nicholas D. SMITH ,  Robert MANSFIELD

IPC: C07D231/12 ,  A61K9/16

Abstract: Described herein is the farnesoid X receptor agonist, trans-N-(3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl)-4-hydroxy-N-((trans-4-(4-methoxy-3-methyl phenyl)cyclohexyl)methyl)cyclohexane-carboxamide, including crystalline forms and pharmaceutically acceptable salts, solvates, and formulations thereof.

公开(公告)号：US20220056019A1

公开(公告)日：2022-02-24

申请号：US17276785

申请日：2019-09-17

Applicant: Metacrine, Inc.

Inventor： Nicholas D. SMITH ,  Steven P. GOVEK ,  Johnny Y. NAGASAWA ,  Andiliy G. LAI ,  Karensa L. DOUGLAS

IPC: C07D413/14 ,  C07D401/14 ,  C07D417/04 ,  C07D403/12 ,  C07D401/12 ,  C07D231/12 ,  C07D405/14 ,  C07D413/04 ,  C07D417/14 ,  C07D403/14 ,  C07D409/14

Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

公开(公告)号：US20210395253A1

公开(公告)日：2021-12-23

申请号：US17349757

申请日：2021-06-16

Applicant: Metacrine, Inc.

Inventor： Nicholas D. SMITH ,  Steven P. GOVEK ,  Karensa L. DOUGLAS ,  Andiliy G. LAI

IPC: C07D471/14 ,  C07D487/04 ,  C07D417/14 ,  C07D413/14

Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

公开(公告)号：US20180251429A1

公开(公告)日：2018-09-06

申请号：US15758712

申请日：2016-09-16

Applicant: Metacrine, Inc.

Inventor： Nicholas D. SMITH ,  Steven P. GOVEK

IPC: C07D217/22 ,  C07D213/75 ,  C07C233/63 ,  C07C233/62 ,  C07D209/42 ,  C07D333/70 ,  C07D215/54 ,  C07D215/48 ,  C07D405/12 ,  C07D401/12 ,  C07D487/04 ,  C07D417/12 ,  A61K45/06 ,  A61K31/44 ,  A61K31/444 ,  A61K31/167 ,  A61K31/404 ,  A61K31/381 ,  A61K31/472 ,  A61K31/47 ,  A61K31/4725

CPC classification number: C07D217/22 ,  A61K31/167 ,  A61K31/381 ,  A61K31/404 ,  A61K31/44 ,  A61K31/444 ,  A61K31/47 ,  A61K31/472 ,  A61K31/4725 ,  A61K45/06 ,  A61P1/16 ,  A61P3/04 ,  C07C233/62 ,  C07C233/63 ,  C07C2601/14 ,  C07D209/32 ,  C07D209/42 ,  C07D213/75 ,  C07D215/48 ,  C07D215/54 ,  C07D333/70 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  C07D487/04

Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

公开(公告)号：US20180244606A1

公开(公告)日：2018-08-30

申请号：US15758709

申请日：2016-09-16

Applicant: Metacrine, Inc.

Inventor： Nicholas D. SMITH ,  Steven P. GOVEK ,  Johnny Y. NAGASAWA

IPC: C07C233/54 ,  A61K45/06 ,  A61K31/216 ,  C07C271/28 ,  A61K31/27 ,  C07C255/57 ,  A61K31/277 ,  C07D309/08 ,  A61K31/351 ,  A61K31/337 ,  C07D305/08 ,  C07D335/02 ,  A61K31/382 ,  C07D205/04 ,  A61K31/397 ,  C07D265/30 ,  A61K31/5375 ,  C07C323/50 ,  C07C317/44 ,  C07D211/94 ,  A61K31/45 ,  C07C235/04 ,  C07C235/40 ,  C07D211/06 ,  A61K31/4453 ,  C07C235/82 ,  C07D231/12 ,  A61K31/415 ,  C07D213/40 ,  A61K31/4406 ,  C07D261/08 ,  A61K31/42 ,  C07D295/135 ,  A61K31/402 ,  C07D231/56 ,  A61K31/416 ,  A61K31/404 ,  C07D209/04 ,  C07D317/58 ,  A61K31/36 ,  C07D295/26 ,  C07D295/195 ,  C07D277/28 ,  A61K31/426 ,  A61K31/4184 ,  C07D235/08 ,  C07D249/18 ,  A61K31/4192 ,  C07D239/42 ,  A61K31/505 ,  C07D241/20 ,  A61K31/4965 ,  C07D237/20 ,  A61K31/50 ,  A61P1/16

CPC classification number: C07C233/54 ,  A61K31/16 ,  A61K31/216 ,  A61K31/27 ,  A61K31/277 ,  A61K31/337 ,  A61K31/351 ,  A61K31/36 ,  A61K31/382 ,  A61K31/397 ,  A61K31/402 ,  A61K31/404 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/426 ,  A61K31/4406 ,  A61K31/4453 ,  A61K31/45 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5375 ,  A61K45/06 ,  A61P1/16 ,  C07C233/63 ,  C07C233/65 ,  C07C233/81 ,  C07C233/87 ,  C07C235/04 ,  C07C235/16 ,  C07C235/40 ,  C07C235/56 ,  C07C235/64 ,  C07C235/82 ,  C07C237/24 ,  C07C255/57 ,  C07C255/60 ,  C07C271/24 ,  C07C271/28 ,  C07C311/07 ,  C07C311/08 ,  C07C317/32 ,  C07C317/44 ,  C07C323/50 ,  C07C323/61 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/16 ,  C07C2602/42 ,  C07C2603/74 ,  C07D205/04 ,  C07D209/04 ,  C07D211/06 ,  C07D211/62 ,  C07D211/76 ,  C07D211/94 ,  C07D211/96 ,  C07D213/40 ,  C07D231/12 ,  C07D231/56 ,  C07D235/04 ,  C07D235/08 ,  C07D237/20 ,  C07D239/42 ,  C07D241/20 ,  C07D249/18 ,  C07D261/08 ,  C07D265/30 ,  C07D277/28 ,  C07D295/088 ,  C07D295/135 ,  C07D295/195 ,  C07D295/26 ,  C07D305/08 ,  C07D309/08 ,  C07D317/58 ,  C07D319/12 ,  C07D335/02 ,  A61K2300/00

Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

公开(公告)号：US20220081390A1

公开(公告)日：2022-03-17

申请号：US17532618

申请日：2021-11-22

Applicant: Metacrine, Inc.

Inventor： Nicholas D. SMITH ,  Steven P. GOVEK ,  Johnny Y. NAGASAWA

IPC: C07C233/80 ,  C07D333/32 ,  C07D239/34 ,  C07D241/18 ,  C07D263/32 ,  C07D205/04 ,  C07D207/27 ,  C07D275/03 ,  C07D277/34 ,  C07D213/65 ,  A61K45/06 ,  C07D207/12 ,  C07D213/75 ,  C07D207/08 ,  C07D213/68 ,  C07D211/42 ,  C07D211/46 ,  C07D213/40 ,  C07D213/64 ,  C07D213/80 ,  C07C271/20 ,  C07C233/63 ,  C07C237/22 ,  C07C237/42 ,  C07C233/59 ,  C07C233/62 ,  A61K31/167 ,  A61K31/216 ,  A61K31/381 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/421 ,  A61K31/425 ,  A61K31/426 ,  A61K31/4418 ,  A61K31/445 ,  A61K31/4965 ,  A61K31/505 ,  C07D207/24 ,  C07D211/94

Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

公开(公告)号：US20210300875A1

公开(公告)日：2021-09-30

申请号：US17152548

申请日：2021-01-19

Applicant: Metacrine, Inc.

Inventor： Nicholas D. SMITH ,  Steven P. GOVEK ,  Johnny Y. NAGASAWA

IPC: C07D231/12 ,  A61P1/16 ,  A61P1/00 ,  A61K9/00 ,  A61K9/06 ,  A61K9/20 ,  A61K9/48 ,  C07D401/04 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D471/04

Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.